Factors effecting impact of Aspergillus fumigatus sensitization in cystic fibrosis.
The clinical impact of Aspergillus fumigatus (Af) sensitization in cystic fibrosis (CF) is controversial. We examined the effect of Af sensitization (Afs) on pulmonary function and growth using a retrospective cohort analysis over two 5-year study periods: 1996-2000 (19 Afs cases and 19 controls) and 2001-2005 (24 Afs cases and 23 controls). Sensitization was defined as Af specific radioallergosorbent test (RAST) >or= 17.5 iu/ml and total serum IgE level >or=150 iu/ml. We examined the impact of changing treatment schedules over these periods. Afs cases had lower median FEV(1) %predicted (%PR) compared to matched controls 1996: 67 versus 80, P < 0.01; 2001: 78 versus 93, P < 0.01. Afs cases in the 2001 cohort had a higher FEV(1) %PR compared to Afs cases in the 1996 cohort: 78 versus 67, P < 0.01. For the 1996 Afs cohort FEV(1) %PR fell significantly over 5 years but not for the 2001 Afs cohort. Af RAST and total IgE reflected the changes in pulmonary function. Children in the 2001 Afs cohort were prescribed significantly more oral antifungal treatment (odds ratio 4.3, 95%CI 1.2-15.7, P = 0.03). Afs children continue to have poorer lung function compared to controls but this observational, hypothesis generating study, suggests that the use of antifungal treatment is associated with better lung function.
Imperial College, London, United Kingdom.
Senthooran Kathirgama
SK
Kanthan
Andrew
A
Bush
Michael
M
Kemp
Roger
R
Buchdahl
D000293:Adolescent; D000935:Antifungal Agents / Q000494:pharmacology*; D001232:Aspergillus fumigatus / Q000187:drug effects / Q000276:immunology*; D016022:Case-Control Studies; D002648:Child; D003550:Cystic Fibrosis / Q000276:immunology* / Q000382:microbiology*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007114:Immunization; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D012189:Retrospective Studies
D000935:Antifungal Agents; D007073:Immunoglobulin E